First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study

IntroductionPembrolizumab stands as a first-line option for patients with advanced non-small cell lung cancer (NSCLC) and high programmed death-ligand 1 (PD-L1) expression (PD-L1 ≥50%). Several factors such as antibiotic exposure, low body mass index (BMI), certain metastatic location or poor perfor...

Full description

Saved in:

Bibliographic Details
Main Authors:	Aida Piedra, Sergio Martínez-Recio, Ainhoa Hernández, Teresa Morán, Edurne Arriola, Jordi Recuero-Borau, Manuel Cobo, Patricia Cordeiro, Joaquín Mosquera, Manuel Fernández, Rosario García-Campelo, Antonio Calles, Rosa Álvarez, María Zapata-García, Dolores Isla, Ana Callejo, Patricia Iranzo, Jorgina Serra-López, Andrés Barba, Ivana Sullivan, Enriqueta Felip, Margarita Majem
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Oncology
Subjects:	pembrolizumab non-small cell lung cancer first-line predictive factors high PD-L1 expression immune check-point inhibitors
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1510278/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study

Similar Items